Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruitingRare disease

Study on the Safety and Effectiveness of Opelconazole with Other Antifungal Treatments for Patients with Hard-to-Treat Lung Aspergillosis

Verified siteInvestigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a condition known as Refractory Invasive Pulmonary Aspergillosis, which is a serious lung infection that does not respond well to standard treatments. The study is testing a new treatment called PC945, which contains the active substance opelconazole. This treatment is delivered as a nebulizer suspension, meaning it is inhaled as a mist directly into the lungs. The trial will compare the effects of PC945 when used alongside other antifungal medications to a placebo, which is a substance with no active medication.

The purpose of the study is to evaluate the safety and effectiveness of PC945 in combination with other antifungal therapies. Participants in the study will receive either the PC945 treatment or a placebo, in addition to their existing antifungal therapy. The study will last for up to 12 weeks, during which time researchers will monitor the participants' responses to the treatment.

Throughout the study, the main focus will be on observing how well the treatment works in improving the condition of those with refractory invasive pulmonary aspergillosis. The goal is to determine if adding PC945 to the current treatment regimen can help achieve a better overall response in managing this challenging lung infection.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, you will be informed about the purpose and procedures involved. This study aims to assess the safety and effectiveness of a medication called PC945 (also known as opelconazole) when used with other antifungal treatments for a lung condition called refractory invasive pulmonary aspergillosis.

  2. Step 2

    Initial assessment

    An initial assessment will be conducted to confirm your eligibility. This includes verifying that your condition meets specific criteria, such as having a proven or probable diagnosis of the lung condition and not responding to previous antifungal treatments.

  3. Step 3

    Randomization

    You will be randomly assigned to receive either the PC945 medication or a placebo. A placebo is a substance with no active medication, used to compare the effects of the actual medication.

  4. Step 4

    Medication administration

    The medication or placebo will be administered through inhalation using a nebulizer. This is a device that turns liquid medicine into a mist, which you breathe in through a mask or mouthpiece.

    The treatment will be given in addition to your existing antifungal therapy. The exact dosage and frequency will be explained to you by the study team.

  5. Step 5

    Monitoring and follow-up

    Throughout the study, your health and response to the treatment will be closely monitored. This includes regular check-ups and assessments to track your progress and any side effects.

    The study will last up to 12 weeks, with evaluations conducted to determine the effectiveness of the treatment.

  6. Step 6

    Completion of the study

    At the end of the study period, a final assessment will be conducted to evaluate your overall response to the treatment.

    The results will help determine the number of participants who experienced a complete or partial improvement in their condition.

Who can join the trial?

6 criteria

  • The participant must have a condition called Refractory Invasive Pulmonary Aspergillosis (IPA). This means the participant has a lung infection caused by a type of fungus, and it has not improved with standard treatment.
  • The participant's IPA must be confirmed as either "proven" or "probable" according to specific medical guidelines. These guidelines are from the 2019 European Organization for Research and Treatment of Cancer/Mycoses Study Group Education and Research Consortium (EORTC/MSGERC) or the 2010 International Society for Heart and Lung Transplantation (ISHLT).
  • The participant's IPA must have not responded to adequate antifungal therapy, meaning the usual treatments have not worked.
  • Participants of all genders are eligible to join the study.
  • The study is open to adults, which typically means individuals aged 18 and older.
  • The study may include individuals considered part of a vulnerable population, which can mean people who might need extra protection or care.

Who cannot join the trial?

8 criteria

  • Patients who are not suffering from Refractory Invasive Pulmonary Aspergillosis cannot participate. This is a specific lung infection that does not respond to standard treatments.
  • Patients who are not within the specified age range cannot participate. The study is open to certain age groups only.
  • Patients who are not part of the specified clinical trial groups cannot participate. This refers to specific categories or classifications of patients that the study is focusing on.
  • Patients who are not able to follow the study procedures or comply with the study requirements cannot participate.
  • Patients who have other medical conditions that might interfere with the study cannot participate.
  • Patients who are pregnant or breastfeeding cannot participate.
  • Patients who are participating in another clinical trial cannot participate.
  • Patients who have a history of allergic reactions to the study medication cannot participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

PC945 is a medication that is being tested in this clinical trial. It is given through a nebulizer, which means it is inhaled directly into the lungs. This medication is being studied to see if it can help treat a lung infection called invasive pulmonary aspergillosis, which is difficult to treat with standard medications. The goal is to see if adding PC945 to the usual treatment can improve the condition of patients who have this infection.

Systemic antifungal therapy refers to the standard treatment that is already used to fight fungal infections in the body. These medications work throughout the entire body to help eliminate the fungus causing the infection. In this trial, systemic antifungal therapy is used alongside PC945 to see if the combination is more effective in treating the lung infection than the standard treatment alone.

What is already known about the treatment

PC945 – PC945 is administered as a nebulized treatment, meaning it is inhaled directly into the lungs using a nebulizer device. It is currently being studied in clinical trials to determine its safety and effectiveness when used alongside other antifungal medications for treating refractory invasive pulmonary aspergillosis, a serious lung infection. The medication works by targeting and inhibiting the growth of the Aspergillus fungus at the molecular level, helping to control the infection. PC945 is classified as an antifungal agent, specifically designed to combat fungal infections in the respiratory system.

Investigated diseases

Refractory Invasive Pulmonary Aspergillosis – This disease is a severe fungal infection of the lungs caused by the Aspergillus species, which is resistant to standard antifungal treatments. It typically occurs in individuals with weakened immune systems, such as those undergoing chemotherapy or organ transplants. The infection begins when the fungal spores are inhaled and settle in the lung tissues, leading to inflammation and tissue damage. As the disease progresses, it can cause symptoms like persistent cough, chest pain, and difficulty breathing. The condition may spread beyond the lungs to other parts of the body if not effectively managed. The progression of the disease can vary depending on the individual's immune response and the effectiveness of any additional treatments.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-511281-36-00Protocol codePC_ASP_006Estimated enrolment123 patientsSponsorPulmocide Limited

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.